Time & Date: 3 September, 13:45 – 14:45 CEST
Chairperson(s): R. Khoramnia GERMANY
Speakers & Presentations:
R. Khoramnia GERMANY
Welcome and introduction
R. Khoramnia GERMANY
The current nAMD treatment paradigm and outstanding unmet needs
V. Sadda USA
Clinical perspective: Brolucizumab (with associated patient management guidance) and its impact on fluid resolution for nAMD patients
D. Chakraborty INDIA
Clinical case studies: Real world experience with brolucizumab*
S. Mahmood UK
Clinical case studies: Brolucizumab in a real world setting
R. Khoramnia GERMANY
Conclusion and Q&A
